Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

NCT02041429 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: Ruxolitinib
DRUG: Paclitaxel

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]